Yoojoo Lim1, Jeong-Ok Lee1, Se Hyun Kim1, Jin Won Kim1, Yu Jung Kim1, Keun-Wook Lee1, Jong Seok Lee1, Soo-Mee Bang2. 1. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. 2. Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea. Electronic address: smbang7@snu.ac.kr.
Abstract
BACKGROUND: Evidences suggest an association between leukocytosis and thrombotic or hemorrhagic complication in polycythemia vera (PV) and essential thrombocythemia (ET), but clinical implication is not well known. OBJECTIVE: To evaluate whether leukocyte burden during follow-up is related to thrombotic or hemorrhagic events in PV and ET. PATIENTS/ METHODS: We retrospectively analyzed patients with PV or ET treated at Seoul National University Bundang Hospital, Korea. Time-weighted averages of leukocytes during the follow-up period were defined as leukocyte burden and were calculated for each patient and compared between patient subgroups. In each patient with events, leukocyte burden for the 3-month period before the event was compared with that for the entire follow-up period. RESULTS: In 102 patients with PV or ET, 35 events (16 thrombotic, 19 hemorrhagic) occurred in 29 patients (median follow-up, 54months). Leukocyte burden were significantly higher in patients with events than in event-free patients (12,015×10(3) /μL vs. 9,567×10(3)/μL, P=0.003). The difference was more prominent in ET patients than in PV patients, and in patients with hemorrhagic events than in those with thrombotic events. In patients with events, the leukocyte burden in the pre-event period was higher than in the entire follow-up period (16,767×10(3)/μL vs. 12,015×10(3)/μL, P=0.002). In all patients, leukocyte burden during entire follow-up period of 11,000×10(3)/μL or higher was an independent risk factor for vascular events. CONCLUSION: In PV or ET patients, leukocyte burden during disease course is related to increased incidence of thrombotic or hemorrhagic events.
BACKGROUND: Evidences suggest an association between leukocytosis and thrombotic or hemorrhagic complication in polycythemia vera (PV) and essential thrombocythemia (ET), but clinical implication is not well known. OBJECTIVE: To evaluate whether leukocyte burden during follow-up is related to thrombotic or hemorrhagic events in PV and ET. PATIENTS/ METHODS: We retrospectively analyzed patients with PV or ET treated at Seoul National University Bundang Hospital, Korea. Time-weighted averages of leukocytes during the follow-up period were defined as leukocyte burden and were calculated for each patient and compared between patient subgroups. In each patient with events, leukocyte burden for the 3-month period before the event was compared with that for the entire follow-up period. RESULTS: In 102 patients with PV or ET, 35 events (16 thrombotic, 19 hemorrhagic) occurred in 29 patients (median follow-up, 54months). Leukocyte burden were significantly higher in patients with events than in event-free patients (12,015×10(3) /μL vs. 9,567×10(3)/μL, P=0.003). The difference was more prominent in ET patients than in PV patients, and in patients with hemorrhagic events than in those with thrombotic events. In patients with events, the leukocyte burden in the pre-event period was higher than in the entire follow-up period (16,767×10(3)/μL vs. 12,015×10(3)/μL, P=0.002). In all patients, leukocyte burden during entire follow-up period of 11,000×10(3)/μL or higher was an independent risk factor for vascular events. CONCLUSION: In PV or ET patients, leukocyte burden during disease course is related to increased incidence of thrombotic or hemorrhagic events.
Authors: Zuzanna Kanduła; Michał Janowski; Barbara Więckowska; Edyta Paczkowska; Krzysztof Lewandowski Journal: J Cancer Res Clin Oncol Date: 2022-10-15 Impact factor: 4.322
Authors: A M Yesilova; S Yavuzer; H Yavuzer; M Cengiz; I D Toprak; E Hanedar; M C Ar; Z Baslar Journal: Int J Hematol Date: 2016-10-03 Impact factor: 2.490
Authors: Hyoung Soo Choi; Junshik Hong; Sang Mee Hwang; Ju Hyun Lee; Youngeun Ma; Sang-A Kim; Ji Yun Lee; Jeong-Ok Lee; Soo-Mee Bang Journal: Ann Hematol Date: 2021-07-30 Impact factor: 3.673
Authors: Mary F F McMullin; Adam J Mead; Sahra Ali; Catherine Cargo; Frederick Chen; Joanne Ewing; Mamta Garg; Anna Godfrey; Steven Knapper; Donal P McLornan; Jyoti Nangalia; Mallika Sekhar; Frances Wadelin; Claire N Harrison Journal: Br J Haematol Date: 2018-11-13 Impact factor: 6.998
Authors: Mohamed S El-Ghonemy; Solafa El Sharawy; Maryan Waheeb Fahmi; Shaimaa El-Ashwah; May Denewer; M A El-Baiomy Journal: Adv Hematol Date: 2020-03-30